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Galectin-3Galectin-3, a ß-galactoside-binding lectin, is found in cellular and extracellular location of the cell and has
pleiotropic biological functions such as cell growth, cell adhesion and cell-cell interaction. It may exhibit anti- or
pro-apoptotic activity depending on its localization and post-translational modiﬁcations. Two important post-
translational modiﬁcations of galectin-3 have been reported: its cleavage and phosphorylation. Cleavage of
galectin-3 was reported to be involved with angiogenic potential and apoptotic resistance. Phosphorylation of
galectin-3 regulates its sugar-binding ability. In this report we have identiﬁed novel tyrosine phosphorylation
sites in galectin-3 aswell as the kinase responsible for its phosphorylation.Our results demonstrate that tyrosines
at positions 79, 107 and 118 can be phosphorylated in vitro and in vivo by c-Abl kinase. Tyrosine 107 is the main
target of c-Abl. Expression of galectin-3 Y107F mutant in galectin-3 null SK-Br-3 cells leads to morphological
changes and increased motility compared to wild type galectin-3. Further investigation is needed to better
understand the functional signiﬁcance of the novel tyrosine phosphorylated sites of galectin-3.+1 313 831 7518.
, makkerp@karmanos.org
raza@karmanos.org (A. Raz).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Galectin-3 is a member of animal lectins that bind β-galactosides
through evolutionarily conserved sequence elements of the carbohy-
drate recognition domain (CRD) [1]. Galectin-3 plays an important role
in tumorigenesis and progression through regulating cell proliferation,
apoptosis, cell adhesion, invasion, angiogenesis and metastasis by
binding to the carbohydrate moiety of cell surface glycoproteins or
glycolipids [2–4]. The coding sequence of galectin-3 gene produces a
protein with calculated molecular weight equal to 26.1 kDa molecular
mass that comprises 250 amino acid residues. However, its apparent
molecular weight as determined by electrophoretic mobility is around
30 kDa [1]. Galectin-3 has a unique chimera type structure consisting of
three different domains: NH2-terminal domain, a repeated collagen-like
sequence rich in proline, glycine, tyrosine and glutamine residues, and a
COOH-terminal domain [2]. The NH2-terminal domain consists of 12
amino acids containing two serine phosphorylation sites at positions 6
and 12, which act as substrates for casein kinase 1 [5]. The serine
phosphorylations appear to be related to ﬁbroblast quiescence/
replicative competence in vitro, lectin export from nuclei, e.g. in
response to apoptotic stress, alterations in signaling/gene expression
with cell-type speciﬁcity and binding ability to its ligands. Serine
phosphorylation of galectin-3 reduces its binding to the glycoprotein
ligands laminin and asialomucin, whereas the dephosphorylation fully
restores the sugar binding activity [6–9].The collagen-like domain contains two matrix metalloproteinases
(MMPs) recognition sites and is made up of repetitive sequence of
nine amino acid residues rich in proline, glycine, tyrosine and
glutamine and lacks charged or large side-chain hydrophobic
residues. The COOH-terminal domain contains a single carbohydrate
recognition domain (CRD) consisting of 140 amino acid residues,
which deﬁnes themolecular characteristics of galectin family, i.e. their
afﬁnity to carbohydrates [2,10,11]. Galectin-3 predominantly localizes
in the cytoplasm, can import into the nucleus through at least two
pathways; via passive diffusion and/or active transport [12,13]. It also
gets secreted from the cytoplasm via the non-classical secretion
pathway, since galectin-3 contains no consensus signal sequence for
either secretion or nuclear translocation [14,15]. Serine phosphory-
lation plays an important role in translocation of galectin-3 between
nucleus and cytoplasm. Galectin-3 also contains the GSK-3ß phos-
phorylation consensus sequence (S92XXXS96). Shimura et al. [16]
demonstrated that phosphorylation of galectin-3 by GSK-3ß is
mediated by Axin. Although the role of this phosphorylation is not
clear yet, it indicates importance of galectin-3 in Wnt pathway.
In 2001 Yamazaki et al. [17] demonstrated that galectin-3 can
also be phosphorylated on tyrosine residues. Their ﬁndings indicated
that galectin-3 is a novel member of signaling proteins downstream
of tyrosine kinase, and suggested that it plays roles in supporting
repair or survival of the injured hepatocytes rather than their
proliferation.
In order to identify the tyrosine phosphorylation sites in galectin-3,
we performed bioinformatic scan and found novel possible sites within
repeated collagen-like sequence rich in glycine, proline tyrosine and
glutamine residues, which can be phosphorylated by c-Abl and Arg (c-
Abl related gene) kinase (Fig 1 I).
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highly conserved in metazoan evolution. c-Abl and the product of its
paralog gene, Arg (ABL2), resemble Src family kinases and consist of a
catalytic domain that is preceded by a variable N-terminal region of 60
or 80 residues, a SH3, and a SH2 domain [18]. Activity of c-Abl protein
is negatively regulated by its SH3 domain, and deletion of the SH3
domain turns c-Abl into an oncogene [19]. The presence of c-Abl in
multiple cellular compartments suggests that the protein might move
from one place to another within the cell, transducing signals in
response to physiological stimuli. Wild-type c-Abl protein does not
transform ﬁbroblasts or hematopoietic cells, even when overex-
pressed, suggesting that Abl kinase activity is regulated tightly in cells
[20]. Deletions and point mutations in the Abl SH3 domain that
prevent binding of proline-rich SH3 ligands, activate c-Abl kinase
activity in vivo, resulting in elevated tyrosine phosphorylation of c-Abl
and other proteins and cellular transformation [18].Fig. 1. (I) Bioinformatic search predicting possible tyrosine phosphorylation sites of galectin
phosphorylation sites and potential kinase. Indicated are NH2-terminal domain, a repeated c
surface accessibility, scores and amino acids around predicted phosphorylation sites. (II)
predicted tyrosine sites and galectin-3 wild type were used as substrate for active c-Abl in i
PAGE gel, and immunoblotted using anti-pTyr antibody (top) or anti-galectin-3 antibody (bo
Line normalization factor, anti-galectin-3 blot was used as reference channel.In the present study we conﬁrm the presence of phosphorylation
at Tyr 79, Tyr 107 and Tyr 118 residues of galectin-3 and demonstrate
that these sites are targeted by c-Abl kinase in vitro as well as in vivo.
2. Materials and methods
2.1. Cell lines and antibodies
The human breast cancer cell line SK-Br-3 and MDA-MB-435 were
maintained in McCoy medium (Invitrogen Corporation) supplemen-
ted with 10% fetal bovine serum (FBS; Atlanta Biologicals). Custom-
ized polyclonal rabbit anti-galectin-3 antibody against the
recombinant whole molecule was created by Zymed Laboratories
(South San Francisco, CA). Monoclonal rat anti-galectin-3 antibody
was isolated from the supernatant of hybridoma TIB-166 (American
Type Culture Collection, Rockville, MD). pTyr blot was performedwith-3 and the cognate protein kinase. (A) A diagram depicting newly identiﬁed galectin-3
ollagen-like sequence and carbohydrate binding domain (CRD). (B) A diagram showing
c-Abl phosphorylation of galectin-3 in vitro. Recombinant GST-Galectin-3 mutants of
n vitro assay. The reaction was stopped by adding sample buffer, resolved on 10% SDS-
ttom). The normalized integrated intensity was calculated as Band integrated intensity/
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icals, Gilbertsville, PA). Mouse anti-ß-actin antibody was purchased
from Sigma-Aldrich (St. Louis, MO).
2.2. Plasmid constructs
Galectin-3 was PCR ampliﬁed from a pcDNA-Gal-3 wild type
vector and subcloned into pECFP, pEGFP (BD Bioresearch, Palo Alto,
CA), pGex-6p (Amersham, Piscataway, NJ), pCMV-Tag1 (Stratagene,
La Jolla, CA) vectors as EcoRI–BamHI, BamHI–EcoRI, BamHI–EcoRI and
BglII–XhoI fragment respectively. pSGT-c-Abl PP and KM was a kind
gift from Dr. Giulio Superti-Furga (Center for Molecular Medicine of
the Austrian Academy of Sciences). c-Abl was PCR ampliﬁed from
pSGT-c-Abl P242/249E (c-Abl PP) and K290M (c-Abl KM) and
subcloned into pEYFP vector (BD Bioresearch, Palo Alto, CA) as
BamHI–HindIII fragment. In experiments using EGFP, ECFP and YCFP-
tagged proteins, images were acquired with an Olympus (Melville,
NY) IX71 microscope supporting a Hamamatsu ORCA-ER video
camera.
2.3. Western blot analysis
Cells were grown up to 80% conﬂuence, and whole-cell lysates
were prepared in lysis buffer [20 mM Tris–HCl (pH 7.4), 0.1% SDS
(Fisher Scientiﬁc, Pittsburgh, PA), 1.0% Triton X-100, 0.25% sodium
deoxycholate, 1 mM EGTA, 1 mM EDTA, 5 mM sodium ﬂuoride, 1 mM
sodium orthovanadate, 1 mM phenylmethylsulfonyl ﬂuoride, 1 μg/ml
leupeptin, 1 μg/ml pepstatin, 1 μg/ml aprotinin (Sigma, St. Louis,
MO). Equal amount of protein was loaded on the gel and resolved by
10% SDS-PAGE and electroblotted onto polyvinylidene diﬂuoride
membrane (Immobilon PSQ, Millipore, MA). Membranes were
quenched in a solution of TBS, containing 0.1% Casein and 0.1%
Tween-20 for 60 min or in 2% Gelatin from cold water ﬁsh skin
(Teleostean gelatin) in case of phosphoblots (Sigma, St. Louis, MO) in
TBST on a rotary shaker. Blots were incubated with appropriate
primary antibodies according to manufactures instructions, washed
and then incubated with appropriate secondary antibodies conjugat-
ed with IRDye 800 (Rockland Immunochemicals, Gilbertsville, PA) or
Alexa Fluor 680 (Invitrogen Corporation) for 30 minutes at room
temperature. After incubation with both primary and the secondary
antibodies, membranes were washed four times with TBST (TBS,
containing 0.1% Tween-20) at 5-min intervals. Immunoblots were
visualized and density of each band was quantitated using the
Odyssey infrared imaging system and Odyssey application software
(LI-COR Biosciences, Lincoln, NE).
2.4. Co-immunoprecipitation assays
Galectin-3 was puriﬁed using rat monoclonal TIB-166 immuno-
precipitation, β-catenin and TCF-4 were puriﬁed using β-catenin and
TCF-4 antibody from BD Bio-Sciences (San Diego, CA). Monoclonal rat
anti-galectin-3 antibody was isolated from the supernatant of
hybridoma (catalogue no. TIB-166; American Type Culture Collection,
Rockville, MD). After extensive washes, galectin-3 presence in the
immunoprecipitates was determined using polyclonal antibody HL31.
Customized polyclonal rabbit anti-galectin-3 antibody against the
recombinant whole molecule was created by Zymed Laboratories
(South San Francisco, CA). 5 mg of cell extracts from exponentially
growing Sk-Br-3 cells were incubated with 10 μg of appropriative
antibody, or control rat IgG precoupled to 50 μl of protein G agarose-
beads (Pharmacia, Uppsala, Sweden) for 2 h at 4 °C. The beads were
washed twice with 10 ml of lysis buffer, twice with 10 ml of lysis
buffer containing 0.5 M LiCl, and twice with 10 ml of phosphate-
buffered saline. Beads were boiled with ×1 sample buffer and loaded
on the gel.2.5. c-Abl kinase assay
c-Abl Kinase assay was preformed using the HTScan Abl1 kinase
assay kit (Cell Signaling Technology, MA) according to the manufac-
turer's instructions.
2.6. Galectin-3 phosphopeptide mapping
Two-dimensional phosphopeptide mapping was performed
according to previously described protocols [21,22]. Brieﬂy, 32P-
labeled recombinant galectin-3 wild type and mutants were resolved
using 10% SDS-PAGE, transferred to a PVDF membrane, excised, and
32P incorporation in galectin-3 was determined by Cherenkov
counting. Following incubation with 0.5% PVP in 100 mM acetic acid
for 30 min at 37 °C and extensive washes, the protein samples were
digested with 10 mg sequencing grade modiﬁed trypsin (Promega,
Madison,WI) in 50 mM ammonium bicarbonate buffer for 2 h at 37 °C
andwith additional 10 mg of trypsin overnight (thismethod routinely
allowed recovery of 90–95% of the initial radioactivity in galectin-3).
The eluted peptides were washed twice with 50 mM ammonium
bicarbonate buffer and once with pH 1.9 TLC-electrophoresis buffer
(2.2% formic acid and 7.8% acetic acid in water). Samples were spotted
on cellulose TLC plates (Merck KGaA, Darmstadt, Germany) and
separated using the Hunter thin-layer chromatography system (CBS
Scientiﬁc, Del Mar, CA) in pH 1.9 buffer for 30 min at 1250 volts. The
plates were dried overnight and subjected to second dimension
chromatographic separation in a phospho-chromatography buffer
(37.5% n-Butanol, 25% Pyridine and 7.5% acetic acid). The plates were
dried and phosphopeptide spots were visualized by autoradiography
and phosphor imaging.
2.7. Wound healing assay
A wound healing assay was performed according to published
protocol [23].
3. Results
3.1. Possible tyrosine phosphorylation sites of galectin-3 by
bioinformatic search
Four possible serine phosphorylations sites within N-terminal and
collagen-like domain were found. Yamazaki et al. [17] demonstrated
that galectin-3 carries tyrosine phosphorylation, however the possible
phosphorylation sites were not revealed in this study. Bioinformatic
search using SCANSITE 2.0 (http://scansite.mit.edu) with low strin-
gency indicates that galectin-3 canbephosphorylatedby c-Abl andArg
kinases on Tyr 79, 107 and 118 (Fig 1 IA). High stringency scan left only
Tyr 107 with a score of 0.3526 and a percentile of 0.046 (Fig. 1 IB).
3.2. Conﬁrmation of tyrosine phosphorylation at predicted sites by
site-directed mutagenesis
To investigate if galectin-3 can be phosphorylated on tyrosine
residues, we substituted the tyrosine residues 79, 107 and 118 with
phenylalanine and created single, double and triple mutants. All
muteins were expressed in bacteria as GST fusion proteins and
puriﬁed as described [24]. Puremuteins as well as wild type galectin-3
were used as substrate for active c-Abl kinase in an in vitro assay
(Fig. 1 II). The results conﬁrm that c-Abl can phosphorylate galectin-3
in vitro. When mutations were performed at the three predicted sites,
phosphorylation of galectin-3 decreased. Tyr 107 is the major residue
phosphorylated by c-Abl kinase as its mutation alone or in
combination with other sites showed minimum phosphorylation of
the protein. These results also indicated the presence of some other
unknown site/s with low stoichiometry. Level of phosphotyrosine
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total galectin-3 in each line using Odyssey 3.0 software.3.3. Conﬁrmation of tyrosine phosphorylation at predicted sites by 2-D
phosphopeptide mapping
To conﬁrm the identity of the phosphorylation sites by an
independent method, we performed 2-D phosphopeptide mapping
of in vitro phosphorylated recombinant muteins and compared its 2-D
tryptic phosphopeptide maps with that of wild type galectin-3 and
CRD domain only (consisting of amino acids 120 to 250) (Fig. 2I).
According to predicted tryptic map all three residues should be
located on the same peptide. The actual tryptic 2-D phosphopeptide
map of wild type galectin-3 shows one major spot with smear around
it and its position on the 2-D map correlates with the predicted
position of a phosphorylated galectin-3 tryptic peptide, while CRD
domain does not show this spot. 2-D phosphopeptide maps of
mutated proteins demonstrate that the mutation in Tyr 107 results in
complete disappearance of the major fraction of phosphorylation,
whereas in other muteins some of the some phosphorylation could be
seen indicating that Tyr 107 is a major phosphorylated site on
galectin-3. Collectively, the phosphopeptide mapping results con-
ﬁrmed the data from Western blot analysis and demonstrate that c-
Abl is responsible for tyrosine phosphorylation of galectin-3 and Tyr
107 is a major phosphorylated site.Fig. 2. (I) Direct phosphorylation of galectin-3 by c-Abl in vitro. Approximately 1 μg of recombi
assay. 100 μl kinase assay buffer containing 100 μM ATP and 25 μCi of [γ-32P] ATP with recom
stoppedwith sample buffer, boiled sampleswere subjected tophosphopeptidemapanalysis asd
type galectin-3 protein was expressed in SK-Br-3 cell with constitutively active c-Abl PP (lane
inhibitor STI571. Galectin-3was immunoprecipitatedusing anti-galectin-3 (TIB166) antibody an
anti-Gal-3 (HL31) (top) and anti-phosphotyrosine antibodies (bottom). (III) Dose-dependent
wild type (lane 1-6) or Y107F (lane 7-12) galectin-3. STI571 was added to cell medium overn
antibodyand loadedongel. The sampleswere resolvedusing10%SDS-PAGEgel and immunoblo
equal loading of immunoprecipitatedproteins 15% of IPmixturewas run on10% SDS-PAGEand v
Band integrated intensity/Lanenormalization factor, anti-galectin-3blotwas usedas reference c
of 1.0. This reference band is then used to calculate the normalization factor for all other selected
band. Then the normalization factor was used to calculate the normalized integrated intensity3.4. In vivo phosphorylation of tyrosine residues
To demonstrate the ability of c-Abl to phosphorylate galectin-3
in vivowe constructed plasmids expressing constitutively active c-Abl
PP and kinase dead mutant c-Abl KM fused with EYFP protein as well
as wild type and Y107F mutant galectin-3 fused with ECFP protein
under the control of the CMV promoter.
SK-Br-3 cells were co-transfected with plasmids expressing EYFP-
c-Abl PP and ECFP-Gal-3. One of the culture dishes was treated with c-
Abl inhibitor STI571. Western blot analysis performed with galectin-3
immunoprecipitated from these cells clearly demonstrates that STI571
treatment resulted in the reduction of tyrosine phosphorylation of
galectin-3 conﬁrming our suggestion that c-Abl is the kinase
responsible for most tyrosine phosphorylations of galectin-3 in the
cells under these conditions (Fig. 2 II lane 2). To address the possibility
that STI571 may block other tyrosine kinases and thus prevent
tyrosine phosphorylation of galectin-3, we co-transfected SK-Br-3
cellswith plasmids expressing EYFP-c-Abl KMand ECFP-Gal-3 (Fig. 2 II
lane 3). A reduction in tyrosine phosphorylation, which was
comparable to STI571 treatment, was observed. That indicates that
other tyrosine kinases in Sk-Br-3 cells phosphorylate galectin-3 with
low stoichiometry under these conditions.
Dose-dependent inhibition of tyrosine phosphorylation in wild type
andY107F galectin-3 is shown in Fig. 2 III. The results show a decrease in
phosphorylation with increasing concentration of the inhibitor. How-
ever, aweak bandcould still be seen athigher concentrations conﬁrmingnant wild-type or mutated galectin-3 proteins used as substrate for active c-Abl in in vitro
binant galectin-3 and active c-Abl was incubated for 20 min at 30 °C. After reaction was
escribed inMaterials andmethods. (II) Phosphorylation of galectin-3by c-Abl in vivo.Wild
1,2) and kinase dead c-Abl KM (lane3). Cells in lane 2 were treated with 10 μM of c-Abl
d loadedongel. The sampleswere resolved using 10% SDS-PAGE and immunoblottedwith
inhibition of c-Abl activity by STI571. SK-Br-3 cells were co-transfected with c-Abl PP and
ight. Cells were lysed and galectin-3 was immunoprecipitated using anti-Gal-3 (TIB166)
ttedwith anti-Gal-3 (HL31) (top) and anti-phosphotyrosineantibody (middle). To conﬁrm
isualizedwith Coomassie blue stain. The normalized integrated intensitywas calculated as
hannel. The bandhaving thehighest integrated intensity is assigneda normalization factor
lanes by dividing the band integrated intensity by the integrated intensity of the reference
.
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site may be present. To ensure that STI571 acts on a timescale that is
consistentwith its use in our experiments, timecourse analysis of STI571
inhibition was performed (data not shown). Both the experiments did
not reveal any signiﬁcant differences between wild type and mutated
protein except difference in the level of total phosphorylation.3.5. Interaction of galectin-3 with c-Abl in vivo
To analyze if galectin-3 and c-Abl exhibit interactions in vivo, we
performed co-immunoprecipitation studies (Fig. 3). MDA-MB-435
cells expressing both galectin-3 and c-Abl were utilized for immuno-
precipitation of galectin-3 with TIB166 antibody in the presence of
sucrose and lactose. Immunoblotting with c-Abl antibody revealed the
presence of c-Abl protein in immunoprecipitatedmixture as well as in
immunoprecipitates with ß-catenin and TCF-4 antibody. ß-catenin
and TCF-4 were used as positive control because their interactions
with c-Abl have been established earlier [25,26]. c-Abl was also found
in immunoprecipitates from cells treated with lactose indicating that
this interaction is not dependent on galectin's carbohydrate-binding
properties.3.6. Effect of tyrosine phosphorylation on cell morphology
To analyze if tyrosine phosphorylation affects cell morphology, SK-
Br-3 cell lines stably expressing EGFP, ECFP-Gal-3 and EGFP-Gal-3
Y107F were established. We decided to use CFP fused galectin-3 wild
type to prevent possible overlap between wild type and mutant
protein labeled with GFP. Selected clones were screened to conﬁrm
the expression of transfected proteins. Cellular phenotypes were
visualized on the second day after splitting (Fig. 4). It is interesting to
notice that cells expressing wild type galectin-3 are different
compared to cells expressing mutated galectin-3 as well as cells
expressing only EGFP protein.3.7. Effect of tyrosine phosphorylation on cell motility
We used SK-Br-3 stable cell lines expressing galectin-3 and Y107F
mutant to examine whether absence of tyrosine phosphorylation at
that position affects cancer cell motility. As shown in Fig. 5, over-
expression of galectin-3 induced cell motility, whereas galectin-3
Y107F did not show a signiﬁcantly increasedmotility compared to the
mock transfected cells. These results suggest that galectin-3 promotes
breast cancer cell motility partially through tyrosine phosphorylation.Fig. 3. Co-immunoprecipitation of c-Abl with Gal-3. MDA-MB-435 cell lysates were
immunoprecipitated using anti-galectin-3 (lanes 1,4,5), anti-TCF-4 (lane 2) and anti-β-
catenin (lane 3) antibody and immunoblotted with anti-c-Abl, anti-TCF-4, anti-β-
catenin and anti-galectin-3 polyclonal antibodies. Some cells were treated with sucrose
and lactose (lines 4, 5, respectively). To conﬁrm equal loading of immunoprecipitated
proteins 15% of IP mixture was run on 10% SDS-PAGE and visualized with Coomassie
blue stain.
Fig. 4. Photomicrograph depicting the morphology of Sk-Br-3 stable cell lines
expressing wild type and Y107F galectin-3. (A) Western blot analysis of Sk-Br-3
clones: transfected with EGFP (lane 1), ECFP-Gal-3 (lane 2) and EGFP-Gal-3 Y107F (lane
3). (B) Cellular shapes were visualized 2 days after splitting. Cells were grown under
identical conditions. Left (phase contrast) and right (ﬂuorescent light) panels represent
same area on plate, ×20.4. Discussion
Galectin-3 is ubiquitously expressed in normal tissues as well as in
a variety of tumors, and the level of expression varies by origin of the
tissue. The intensity of its expression and localization depends on
tumorigenicity, invasiveness andmetastatic potential of a cell and has
resulted in the use of galectin-3 as a biomarker for variety of tumors.
Galectin-3 can shuttle between the nucleus and the cytoplasm [27–29]
and is involved in the fundamental processes such as pre-mRNA
splicing [30], cell-cycle progression [31,32], proliferation [33], and
apoptosis [34–37] mainly through intracellular protein-protein inter-
actions and lectin-carbohydrate interactions. However, the functions
of galectin-3 are regulated not only by its expression level and cellular
localization, but also by post-translational modiﬁcations like
Fig. 5. Wound healing assay of SK-Br-3 cells were performed with stable cell lines constitutively expressing galectin-3 wild type and galectin-3 Y107F mutant. Cells were grown
under identical conditions.
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phorylated at different serine residues with serine 6 being the main
site phosphorylated by casein kinase I [5]. Protein phosphorylated at
serine 6 showed reduced binding to laminin and asialomucin.
Dephosphorylation of galectin-3 restored the sugar binding capacity.
Interestingly, mutations at serine 6 resulted in a diminished ability of
galectin-3 to protect cells from cisplatin-induced apoptosis [5]. GSK-
3ß is responsible for phosphorylation of serine 92 and 96 and these
phosphorylations are mediated by Axin [16]. The biological signiﬁ-
cance of these phosphorylation sites has not been reported so far.
As early as in 2001, phosphorylation of tyrosine residue/s of
endogenous galectin-3 was demonstrated for the ﬁrst time. However
the position of the phosphorylated tyrosine residue/s and tyrosine
kinase that phosphorylates galectin-3 was not determined [17]. The
authors demonstrated that the hepatic galectin-3 has the potential to
function as a novel member of signaling proteins downstream of
unknown tyrosine kinase. Although the nature of the interaction was
unclear, Menon and Hughes hypothesized that galectin-3 can interact
with proteins carrying SH3 domains through PXXP motifs found in
primary structure of galectin-3 [38].
c-Abl kinase is a tyrosine kinase containing a SH3 domain, and has
been implicated in the processes of cell differentiation, cell division, cell
adhesion, and stress response. Truncated c-Abl can fuse with other
genes and turn oncogenic: for example in the case of Bcr (breakpoint
cluster region)-abl [39]. Our results on the in vitro phosphorylation of
wild type, single, double and triple mutants of galectin-3 as substrate
conﬁrmed that c-Abl is the kinase responsible for phosphorylation of
galectin-3 (Fig. 1, II). Immunoblotting studies with anti-phosphotyr-
osine antibody and 2-D phosphopeptide mapping point out that the
main phosphorylation site on galectin-3 is tyrosine 107. Although
bioinformatic search suggested that all three tyrosines at amino acid
position 79, 107 and 118 can be phosphorylated, our results (Fig. 1 and
2) clearly demonstrate that c-Abl can phosphorylate some other yetunknown tyrosine residue/s since some of the phosphorylation could
still be seen even in triple mutant. In vivo experiment (Fig. 2, II) also
indicates the possibility of other yet unknown tyrosine kinase/s to
phosphorylate galectin-3 as weak bands were observed in cells treated
with c-Abl inhibitor STI571 and cell co-transfected with kinase dead c-
Abl. The phosphorylation may play a role in the interactions of galectin-
3 with other proteins that are targeted by c-Abl kinase. It was reported
that galectin-3 binds to β-catenin/TCF-4 complex, co-localizes with β-
catenin in the nucleus, and induces the transcriptional activity of TCF-4
leading to up-regulation cyclin D1 and c-myc expression [33]. Bcr-Abl
and active c-Abl physically interact with β-catenin, and its oncogenic
tyrosine kinase activity is required to phosphorylate β-catenin at
tyrosine 86 and tyrosine 654 residues. β-catenin with these post-
translational modiﬁcations binds to the TCF-4 transcription factor, thus
representing a transcriptionally active pool that is responsible for
increased expression of cyclinD1 and c-myc [26]. Our results suggest the
possibility that the nuclear localization and activation of β-catenin may
be dependent on its interaction with galectin-3 as well as its tyrosine
phosphorylation triggered by active c-Abl.
Although our results demonstrate that tyrosine 107 is the main
target of c-Abl kinase, however, we cannot exclude the possibility that
in other environments the main phosphorylation site can be different
or all three tyrosine residues can be equally phosphorylated. Since the
in vitro studies indicate a clear interaction between c-Abl and galectin-
3, we analyzed this interaction in vivo utilizing immunoprecipitation
techniques. Immunoprecipitated galectin-3 pulled-down endogenous
c-Abl together with other proteins even in presence of lactose
indicating that binding of galectin-3 to c-Abl is independent of
carbohydrate binding properties of galectin-3. This ﬁnding strength-
ens the hypothesis of Menon and Hughes that c-Abl and galectin-3
interaction involve SH3 domain of c-Abl.
Next, in vivo experiments were performed in breast cancer cell cells
SK-Br-3; that do not express galectin-3 and c-Abl, the results show that
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phosphorylation of galectin-3 in SK-Br-3 cells (Fig. 2 II). However this
ﬁnding does not exclude the possibility that in other cells galectin-3 can
be targeted by various tyrosine kinases.
Next we co-transfected wild type or Y107F galectin-3 with
constitutively active c-Abl PP in SK-Br-3 cells and studied the effect
of the c-Abl inhibitor STI571 in a dose dependent manner. Although
the total level of tyrosine phosphorylation was lower in case of
mutated galectin-3, kinetic of phosphorylation was similar pointed
out that this mutation does not change the afﬁnity of the two proteins.
We also measured the time course of STI571 inhibition for c-Abl.
Wild type and mutant galectin-3 were immunoprecipitated after
incubation with STI571 for various amounts of time. The phosphor-
ylation of galectin-3 drop signiﬁcantly upon STI571 addition, with
maximum inhibition being achieved in approximately 6 h (data not
shown). These experiments show that the majority of c-Abl inhibition
occurs within ﬁrst hour and conﬁrm our previous data that Y107F
mutation does not change the afﬁnity between c-Abl and galectin-3.
To study the effect of galectin-3 tyrosine phosphorylation cell
morphology we created SK-Br-3 cell clones stably expressing GFP
protein only, GFP-Gal-3 and CFP-Gal-3 Y107F. Although, both wild
type and Y107F mutant protein clones expressed galectin-3 at equal
levels, SK-Br-3 cells expressing wild type galectin-3 were much
smaller and rounded compared to cells expressing GFP protein only
and mutated galectin-3. As the changes in cell shape are associated
with cytoskeleton reorganization and focal adhesion, in addition to a
plethora of other biological responses and altered by speciﬁc external
stimuli, we presume that the observed differences in cell shape could
be either due to interaction of phosphorylated galectin-3 with
cytoskeleton proteins directly or interactions with receptor proteins
and thus vary the signaling output. As a result, the cells harboringwild
type protein are smaller in size andmoremotile compared to the ones
carrying mutated protein. Trans-membrane crosstalk between the
galectin-3 lattice and caveaolin-1 phosphorylated by c-Abl on tyrosine
14 promotes focal adhesion (FA) turnover by stabilizing FA kinase
within FAs deﬁning interdependent roles for galectin-3 and pY14Cav1
in tumor cell migration [40,41]. Our experiments did not reveal any
signiﬁcant difference in subcellular localization of galectin-3 between
wild type and Y107F mutant, therefore we presume that the
differences in cell morphology could be due to altered interactions
with the binding partners in the two variants.
Recent data demonstrate that galectin-3 is a centrosome-associated
protein that is required for epithelial morphogenesis [42]. One of the
functions of centrosome is to control key aspects of cell morphology
necessary for normal development. We can suggest that the galectin-3
and centrosome interaction dependent from tyrosine phosphorylation
and can affect cell morphology through this mechanism. Further
investigation is needed to better understand the functional signiﬁcance
of novel tyrosine phosphorylated sites of galectin-3.
Galectin-3 regulates intrinsic cell motility by regulating the
activity of transcriptional factors and its over-expression results in
enhanced adhesion to extracellular matrix components, cell motility,
and in vitro invasiveness [43,44]. Our results demonstrate that cells
expressing galectin-3 Y107F variant showed reduced migration in
wound healing assay (Fig. 5). This result conﬁrms the role of galectin-
3 tyrosine phosphorylation in cell motility. Since c-Abl kinase is either
not expressed in SK-Br-3 cells or its expression level is very low, we
assumed that the observed effects are the result of galectin-3
phosphorylation by other as yet unknown kinase/s.
It will be of interest to determine the effects of phosphorylation of
tyrosine 107 by c-Abl kinase on other phosphorylation events of
galectin-3 and vice versa, to explore the potential regulatory role of each
phosphorylation event on the other. In summary, this novel ﬁnding
shows that c-Abl is responsible for tyrosine phosphorylation of galectin-
3 at residues Tyr 79, 107and 118 andTyr 107 is amajor phosphorylation
site.Off note: when this work was in progress Li et al. [45] published
the paper where conﬁrmed by indirect methods phosphorylations of
two sites from three sites.
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